the new h2 receptor antagonist , famotidine , has been tested in open and double-blind studies in over 2,000 acute duodenal or gastric ulcer patients as well as in the maintenance of chronic duodenal ulcer patients .
C0015620
famotidine
C0038358
gastric ulcer